Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 6/10

vs
industry
vs
history
Cash to Debt No Debt
MEOBF's Cash to Debt is ranked higher than
90% of the 845 Companies
in the Global Biotechnology industry.

( Industry Median: 67.24 vs. MEOBF: No Debt )
Ranked among companies with meaningful Cash to Debt only.
MEOBF' s 10-Year Cash to Debt Range
Min: No Debt  Med: 10000.00 Max: No Debt
Current: No Debt
Equity to Asset 0.64
MEOBF's Equity to Asset is ranked lower than
56% of the 600 Companies
in the Global Biotechnology industry.

( Industry Median: 0.69 vs. MEOBF: 0.64 )
Ranked among companies with meaningful Equity to Asset only.
MEOBF' s 10-Year Equity to Asset Range
Min: 0.64  Med: 0.69 Max: 0.97
Current: 0.64
0.64
0.97
F-Score: 1
Z-Score: 1.59
M-Score: -3.41
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -604.75
MEOBF's Operating margin (%) is ranked lower than
75% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -69.59 vs. MEOBF: -604.75 )
Ranked among companies with meaningful Operating margin (%) only.
MEOBF' s 10-Year Operating margin (%) Range
Min: -39225  Med: -506.06 Max: 2.77
Current: -604.75
-39225
2.77
Net-margin (%) -535.44
MEOBF's Net-margin (%) is ranked lower than
74% of the 663 Companies
in the Global Biotechnology industry.

( Industry Median: -66.45 vs. MEOBF: -535.44 )
Ranked among companies with meaningful Net-margin (%) only.
MEOBF' s 10-Year Net-margin (%) Range
Min: -29639.29  Med: -415.52 Max: 307.32
Current: -535.44
-29639.29
307.32
ROE (%) -16.76
MEOBF's ROE (%) is ranked higher than
59% of the 763 Companies
in the Global Biotechnology industry.

( Industry Median: -29.44 vs. MEOBF: -16.76 )
Ranked among companies with meaningful ROE (%) only.
MEOBF' s 10-Year ROE (%) Range
Min: -56.2  Med: -28.55 Max: 33.17
Current: -16.76
-56.2
33.17
ROA (%) -10.51
MEOBF's ROA (%) is ranked higher than
63% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -25.50 vs. MEOBF: -10.51 )
Ranked among companies with meaningful ROA (%) only.
MEOBF' s 10-Year ROA (%) Range
Min: -48.97  Med: -25.17 Max: 22.79
Current: -10.51
-48.97
22.79
ROC (Joel Greenblatt) (%) -39.39
MEOBF's ROC (Joel Greenblatt) (%) is ranked higher than
65% of the 822 Companies
in the Global Biotechnology industry.

( Industry Median: -343.99 vs. MEOBF: -39.39 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
MEOBF' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -24438.43  Med: -5990.14 Max: 23350.19
Current: -39.39
-24438.43
23350.19
Revenue Growth (3Y)(%) -29.10
MEOBF's Revenue Growth (3Y)(%) is ranked lower than
73% of the 406 Companies
in the Global Biotechnology industry.

( Industry Median: 1.10 vs. MEOBF: -29.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
MEOBF' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0  Med: 0.00 Max: -29.1
Current: -29.1
» MEOBF's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Insider Trades

Latest Guru Trades with MEOBF

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 1.95
MEOBF's P/B is ranked higher than
78% of the 746 Companies
in the Global Biotechnology industry.

( Industry Median: 4.54 vs. MEOBF: 1.95 )
Ranked among companies with meaningful P/B only.
MEOBF' s 10-Year P/B Range
Min: 1.63  Med: 2.75 Max: 4.52
Current: 1.95
1.63
4.52
P/S 67.02
MEOBF's P/S is ranked lower than
85% of the 596 Companies
in the Global Biotechnology industry.

( Industry Median: 11.64 vs. MEOBF: 67.02 )
Ranked among companies with meaningful P/S only.
MEOBF' s 10-Year P/S Range
Min: 52  Med: 70.00 Max: 105.33
Current: 67.02
52
105.33
EV-to-EBIT -11.34
MEOBF's EV-to-EBIT is ranked lower than
473% of the 227 Companies
in the Global Biotechnology industry.

( Industry Median: 32.48 vs. MEOBF: -11.34 )
Ranked among companies with meaningful EV-to-EBIT only.
MEOBF' s 10-Year EV-to-EBIT Range
Min: -32.8  Med: -16.70 Max: -7.5
Current: -11.34
-32.8
-7.5
Current Ratio 4.77
MEOBF's Current Ratio is ranked higher than
53% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. MEOBF: 4.77 )
Ranked among companies with meaningful Current Ratio only.
MEOBF' s 10-Year Current Ratio Range
Min: 1.82  Med: 6.96 Max: 21
Current: 4.77
1.82
21
Quick Ratio 4.77
MEOBF's Quick Ratio is ranked higher than
55% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: 4.17 vs. MEOBF: 4.77 )
Ranked among companies with meaningful Quick Ratio only.
MEOBF' s 10-Year Quick Ratio Range
Min: 1.82  Med: 6.96 Max: 21
Current: 4.77
1.82
21
Days Sales Outstanding 166.90
MEOBF's Days Sales Outstanding is ranked lower than
88% of the 564 Companies
in the Global Biotechnology industry.

( Industry Median: 60.21 vs. MEOBF: 166.90 )
Ranked among companies with meaningful Days Sales Outstanding only.
MEOBF' s 10-Year Days Sales Outstanding Range
Min: 26.01  Med: 190.90 Max: 1147.14
Current: 166.9
26.01
1147.14

Valuation & Return

vs
industry
vs
history
Price/Projected FCF 4.62
MEOBF's Price/Projected FCF is ranked lower than
54% of the 136 Companies
in the Global Biotechnology industry.

( Industry Median: 5.34 vs. MEOBF: 4.62 )
Ranked among companies with meaningful Price/Projected FCF only.
MEOBF' s 10-Year Price/Projected FCF Range
Min: 3.45  Med: 4.39 Max: 6.57
Current: 4.62
3.45
6.57
Price/Median PS Value 0.83
MEOBF's Price/Median PS Value is ranked higher than
65% of the 505 Companies
in the Global Biotechnology industry.

( Industry Median: 1.14 vs. MEOBF: 0.83 )
Ranked among companies with meaningful Price/Median PS Value only.
MEOBF' s 10-Year Price/Median PS Value Range
Min: 0.87  Med: 1.15 Max: 1.16
Current: 0.83
0.87
1.16
Earnings Yield (Greenblatt) (%) -8.80
MEOBF's Earnings Yield (Greenblatt) (%) is ranked lower than
55% of the 817 Companies
in the Global Biotechnology industry.

( Industry Median: -5.40 vs. MEOBF: -8.80 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
MEOBF' s 10-Year Earnings Yield (Greenblatt) (%) Range
Min: -8.8  Med: 0.10 Max: 0.1
Current: -8.8
-8.8
0.1

Analyst Estimate

Jun15 Jun16 Jun17 Jun18
Revenue(Mil) 42 101 252 808
EPS($) -0.24 -0.18 0.14 1.22
EPS without NRI($) -0.24 -0.18 0.14 1.22

Business Description

Industry: Biotechnology » Biotechnology
Compare: » details
Traded in other countries:MSB.Australia, LWB.Germany,
Mesoblast Ltd is an Australian biotechnology company. The Company is engaged in the development, manufacturing and commercialization of biological products for the field of regenerative medicine. Its products are for cardiovascular conditions, diabetes, inflammatory conditions of lungs and joints, eye diseases, bone marrow cancers, bone fractures, cartilage degeneration and musculoskeletal conditions. The Company and Teva Pharmaceutical Industries Ltd., have established a strategic alliance to commercialize adult stem cell products for degenerative conditions of the cardiovascular and central nervous systems. The alliance also extends to products for augmenting bone marrow transplantation in cancer patients.

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK